Grothey A - Search Results

1

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Franko J, et al. Among authors: grothey a. Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12. Lancet Oncol. 2016. PMID: 27743922 Free article. Clinical Trial.

2

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Grothey A, et al. J Clin Oncol. 2004 Apr 1;22(7):1209-14. doi: 10.1200/JCO.2004.11.037. J Clin Oncol. 2004. PMID: 15051767

3

FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.

Grothey A, Sargent DJ. Grothey A, et al. J Clin Oncol. 2005 May 20;23(15):3311-3. doi: 10.1200/JCO.2005.11.691. J Clin Oncol. 2005. PMID: 15908645 No abstract available.

4

Clinical trial designs for prospective validation of biomarkers.

Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Mandrekar SJ, et al. Among authors: grothey a. Am J Pharmacogenomics. 2005;5(5):317-25. doi: 10.2165/00129785-200505050-00004. Am J Pharmacogenomics. 2005. PMID: 16196501

5

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Sargent DJ, et al. Among authors: grothey a. J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260700

6

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.

Grothey A, Sargent D. Grothey A, et al. J Clin Oncol. 2005 Dec 20;23(36):9441-2. doi: 10.1200/JCO.2005.04.4792. J Clin Oncol. 2005. PMID: 16361649 No abstract available.

7

First- and second-line therapy of metastatic colorectal cancer.

Terstriep S, Grothey A. Terstriep S, et al. Among authors: grothey a. Expert Rev Anticancer Ther. 2006 Jun;6(6):921-30. doi: 10.1586/14737140.6.6.921. Expert Rev Anticancer Ther. 2006. PMID: 16761936 Review.

8

Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.

Grothey A. Grothey A. Semin Oncol. 2006 Oct;33(5 Suppl 10):S41-9. doi: 10.1053/j.seminoncol.2006.08.004. Semin Oncol. 2006. PMID: 17145524 Review.

9

Is there a third-line therapy for metastatic colorectal cancer?

Grothey A. Grothey A. Semin Oncol. 2006 Dec;33(6 Suppl 11):S36-8. doi: 10.1053/j.seminoncol.2006.10.007. Semin Oncol. 2006. PMID: 17178284 Review.

10

Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.

Grothey A, Marshall JL. Grothey A, et al. Oncology (Williston Park). 2007 Apr;21(5):553-64, 566; discussion 566-8, 577-8. Oncology (Williston Park). 2007. PMID: 17536342 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page